top of page


European Commission approves Tecvayli monotherapy from first relapse in multiple myeloma
The European Commission has approved Johnson & Johnson's Tecvayli monotherapy from first relapse in multiple myeloma, moving the bispecific antibody into an earlier treatment setting.

nuaxia
Oct 272 min read


FDA Approves Tecvayli Plus Darzalex Faspro for Relapsed or Refractory Multiple Myeloma
Combination therapy demonstrates significant improvements in progression-free and overall survival in adults after at least one prior treatment, offering a new standard-of-care option.

nuaxia
Mar 92 min read
bottom of page